C
C. Han
Researcher at Janssen Pharmaceutica
Publications - 40
Citations - 611
C. Han is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 32 publications receiving 582 citations.
Papers
More filters
Journal ArticleDOI
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
Josef S Smolen,C. Han,Mohan Bala,Ravinder Nath Maini,J. R. Kalden,D. van der Heijde,F. C. Breedveld,Daniel E. Furst,Peter E. Lipsky +8 more
TL;DR: Even in patients without clinical improvement, treatment with infliximab plus MTX provided significant benefit with regard to the destructive process, suggesting that in such patients these 2 measures of disease are dissociated.
Journal ArticleDOI
Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis
F. C. Breedveld,C. Han,Mohan Bala,D. van der Heijde,David Baker,Arthur Kavanaugh,Ravinder Nath Maini,Peter E. Lipsky +7 more
TL;DR: Greater joint damage at baseline was associated with poorer physical function at baseline and less improvement in physical function after treatment, underlining the importance of early intervention to slow the progression of joint destruction.
Journal ArticleDOI
The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease.
Bruce E. Sands,C. Han,Christopher Gasink,Douglas Jacobstein,Philippe Szapary,Long-Long Gao,Yinghua Lang,Stephan R. Targan,William J. Sandborn,Brian G. Feagan +9 more
TL;DR: Ustekinumab improved HRQOL in patients with moderately to severely active CD, and greater proportions of ustek inumab-treated patients in both studies had clinically meaningful improvements in PCS and MCS as compared with placebo.
Journal ArticleDOI
FRI0266 Health-Related Quality of Life of Patients with Rheumatoid Arthritis Achieving DAS28 Remission, Improvement in Physical Function and NO Radiographic Progression after Treatment with Intravenous Golimumab
Rene Westhovens,Michael E. Weinblatt,C. Han,L. Kim,Michael Mack,J. Lu,David Baker,Alan M. Mendelsohn,Clifton O. Bingham +8 more
TL;DR: Patients who achieved “comprehensive remission” at week 24 achieved numerically greater improvement in normalized HRQOL in SF-36 PCS and MCS and in FACIT-fatigue, and were more likely to regain employability at Week 24, 52 or week 112.